Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | Q9HBH1 | 1/20 | 0.45 | |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | FURIN | P09958 | 3/20 | 0.41 |
| ▸ | MMP3 | P08254 | 4/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27291531 | 0.90 | FURIN (0.49) | PDFCA1CA2KLKB1FURIN | |
| SCHEMBL24414345 | 0.86 | FURIN (0.41) | FURINMMP3SPHK1 | |
| SCHEMBL24101424 | 0.82 | SSTR3 (0.54) | PDFMMP3MMP1PLGSSTR3 | |
| SCHEMBL24393479 | 0.81 | PDF (0.44) | PDFCA1CA2KLKB1FURIN | |
| SCHEMBL27291534 | 0.81 | FURIN (0.48) | PDFCA1CA2KLKB1FURIN | |
| SCHEMBL25993246 | 0.80 | SMN1; SMN2 (0.40) | SPHK1 | |
| SCHEMBL24101234 | 0.80 | SMN1; SMN2 (0.40) | SPHK1 | |
| SCHEMBL24393476 | 0.79 | FURIN (0.40) | FURINMMP3 | |
| SCHEMBL24864487 | 0.79 | KLKB1 (0.44) | PDFCA1CA2KLKB1FURIN | |
| SCHEMBL21965275 | 0.78 | FURIN (0.41) | FURINSPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024094688-A1 | ANTI-GUCY2C ANTIBODY AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2024-05-10 | — | — | WO | disclosed |
| US-20230355792-A1 | METHODS OF IMPROVING THE THERAPEUTIC INDEX | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-11-09 | — | — | US | disclosed |
| WO-2023194539-A1 | METHODS OF IMPROVING THE THERAPEUTIC INDEX OF AMATOXIN-ANTIBODY CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-10-12 | — | — | WO | disclosed |
| US-20230220001-A1 | METHOD FOR SYNTHESIS OF THIOETHER-CONTAINING PEPTIDES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| WO-2022194988-A2 | B-LYMPHOCYTE SPECIFIC AMATOXIN ANTIBODY CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022096604-A1 | COMPOSITION COMPRISING A COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND ANTIBODY-AMATOXIN CONJUGATE FOR USE IN CANCER THERAPY | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021250059-A1 | METHOD FOR SYNTHESIS OF THIOETHER-CONTAINING PEPTIDES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355792-A1 | METHODS OF IMPROVING THE THERAPEUTIC INDEX | CD47, ANXA5, MTX1 | PDF 1554/4885CA1 419/4885CA2 949/4885 |
| US-20230220001-A1 | METHOD FOR SYNTHESIS OF THIOETHER-CONTAINING PEPTIDES | TST, PTMS, CTH | PDF 286/4885CA1 492/4885CA2 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.